首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

1942284

失眠症市場規模、佔有率、趨勢和預測（按治療類型、藥物類別、分銷管道和地區分類），2026-2034年

Insomnia Market Size, Share, Trends and Forecast by Therapy Type, Drug Class, Distribution Channel, and Region, 2026-2034

出版日期: 2026年02月01日 | 出版商:

IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2025年全球失眠市場規模為55億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到68億美元，2026年至2034年的複合年成長率（CAGR）為2.45%。北美目前佔據市場主導地位，預計2025年將佔據超過36.4%的市場。推動市場成長的關鍵因素包括：現代生活方式和壓力導致失眠盛行率上升；診斷技術進步提高了診斷準確性；積極開展新型治療方法的研究；醫療費用支出增加；數位化醫療解決方案的整合；策略性產業合作；以及消費者對非藥物療法的偏好日益成長。此外，先進的醫療環境、睡眠障礙的高盛行率以及創新治療方法的應用也進一步推動了失眠市場佔有率的成長。

現代生活方式、壓力和人口老化導致睡眠障礙病例增加，這是失眠市場的主要促進因素。診斷技術的進步提高了診斷的準確性，而對新型治療方法的研究則拓展了治療選擇。醫療保健成本的上升以及包括睡眠追蹤應用程式和遠端醫療在內的數位化醫療解決方案的普及，都在推動市場成長。例如，Emma-The Sleep Company 於 2024 年 3 月推出的「Emma Up」是一款創新的 AI 睡眠指導應用程式，它採用基於聲音的睡眠追蹤技術。該應用程式滿足了超過 73% 用戶改善睡眠品質的需求，並提供個人化分析以應對睡眠挑戰。消費者對非藥物療法（例如失眠認知行為療法）的需求以及政府的各項舉措，也為全球失眠市場帶來了積極前景。

美國失眠市場的主要促進因素是壓力、久坐的生活方式和人口老化導致的睡眠障礙高發生率。人們對睡眠健康及其對整體健康影響的認知不斷提高，推動了對有效治療方法的需求。診斷工具和治療方法的進步，特別是睡眠應用程式和遠端醫療等數位健康技術，進一步體現了美國失眠市場的一些關鍵趨勢。例如，SleepScore Labs於2024年10月發布了“Sleep.AI”，這是第一個基於實證醫學的睡眠健康人工智慧平台，利用了超過5億小時的睡眠數據和230多項研究成果。非藥物療法，特別是針對失眠的認知行為療法（CBT），正受到消費者的青睞。此外，大規模的研究投入、不斷上漲的醫療保健成本以及支持性的保險政策也在推動美國失眠市場的發展。

失眠市場趨勢：

壓力、焦慮和精神疾病呈上升趨勢

sutoresu、不安、および精神疾患の発生率増加が市場に好影響を與えています。米國精神醫學會が2024年ル2024年には成人の43％が202 3年と比較してより強い不安を感じたと報告しており、これは2023年の37％、2022年の32％から増加しています仕事のプラッシャー、デジタル機器による關注散漫、社會課題といった現代の生活様式は、広範な睡眠障礙害を引き起こしています。慢性的なsutoresuホルモンバransuに影響を與え、睡眠,覚醒サイクルを亂すことぁめめめめもすあぁぁめめめめめめめめめめめめめめめめぁめぁめぁ、ぁさらに、不安や憂鬱症病は睡眠障礙害と存並することが醫療多く、的介入の需要を高めています。メンタルウェルネsuに対する社會意識の高まりは、より多くの人々が専門家の助けを求めるよう助し、睡眠薬や治療の増加につながっています。制定薬企業は、sutoresu關連の不眠症に特化した、より安全で依存性の低い薬剤や認知行動治療を開癁のすいます。在全球心理健康挑戰日益嚴峻的背景下，心理健康與睡眠健康之間日益密切的聯繫仍然是推動市場擴張的核心因素。

人口老化和睡眠障礙風險增加

全球人口老化是失眠市場成長的重要推動因素。根據世界衛生組織預測，到2030年，全球六分之一的人口將達到或超過60歲。老年人更容易受到與老齡化相關的生理變化、慢性疾病和藥物副作用的影響，從而出現睡眠障礙。關節炎、心血管疾病和神經系統疾病等常常會擾亂正常的睡眠模式。此外，褪黑激素分泌會隨著老齡化成長而減少，這使得老年人更難維持規律的睡眠週期。預期壽命的延長和健康意識的提高促使越來越多的老年人尋求睡眠相關問題的醫療幫助。這種人口結構的變化導致對處方藥、行為療法和天然助眠產品的需求不斷成長。與老齡化相關的睡眠障礙是推動市場發展的關鍵因素之一，因為醫療保健機構正致力於提供針對老年人需求的整體睡眠管理方案。

數位生活風格和螢幕曝光量的增加

對電子設備的日益依賴和螢幕使用時間的延長為市場帶來了有利前景。根據行業報告顯示，到2024年第三季度，全球16至64歲的用戶平均每天將在各種設備的螢幕前花費6小時38分鐘。智慧型手機、平板電腦和電腦發出的藍光會抑制褪黑激素的分泌，擾亂自然睡眠週期，導致入睡困難。遠距辦公、深夜娛樂活動和社交媒體的使用加劇了各個年齡層的這一問題。持續的線上狀態和過度刺激會提升認知警覺性，阻礙充分休息。隨著人們對電子設備引起的睡眠障礙的認知不斷提高，消費者開始尋求助眠產品、行動應用程式和療法來改善睡眠品質。製藥和健康公司正透過褪黑激素補充劑、行為療法和正念練習等方式來解決這一現代生活方式問題。螢幕生活方式的持續發展確保了臨床和消費者健康市場對失眠治療的穩定需求。

The global insomnia market size was valued at USD 5.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 6.8 Billion by 2034, exhibiting a CAGR of 2.45% during 2026-2034. North America currently dominates the market, holding a significant market share of over 36.4% in 2025. Increasing prevalence due to modern lifestyles and stress, advancements in diagnostic technologies enhancing accuracy, robust research into novel therapies, rising healthcare expenditures, integration of digital health solutions, strategic industry collaborations, and growing consumer preference for non-pharmacological treatments are some of the factors bolstering the market growth. In addition to this, advanced healthcare, high sleep disorder prevalence, and adoption of innovative treatments are further increasing the insomnia market share.

The key drivers in the insomnia market are increasing prevalence of sleep disorders due to modern lifestyles, stress, and aging populations. Advances in diagnostic technologies improve accuracy while research into novel therapies is increasing the treatment options. Increasing healthcare expenditures and the adoption of digital health solutions including sleep-tracking apps and telemedicine are fueling growth in the market. For instance, in March 2024, Emma Up launched by Emma - The Sleep Company is an innovative AI sleep coaching app featuring sound-based sleep tracking. It offers personalized insights to tackle sleep issues addressing over 73% of users' desire for better sleep quality. Consumer demand for non-pharmacological treatments like cognitive behavioral therapy for insomnia and government initiatives are also creating a positive insomnia market outlook across the world.

The key drivers in the United States insomnia market are the high prevalence of sleep disorders associated with stress, sedentary lifestyles and aging populations. Increased awareness of the importance of sleep health and its impact on overall well-being is driving demand for effective treatments. Advances in diagnostic tools and therapeutic options including digital health technologies like sleep apps and telemedicine further represent some of the key insomnia market trends in the country. For instance, in October 2024, SleepScore Labs launched Sleep.AI the first evidence-based AI platform for sleep health utilizing over 500 million hours of sleep data and insights from 230+ studies. Increasing non-pharmacological treatments especially cognitive behavioral therapy for insomnia are gaining momentum among consumers. Moreover, extensive research investments, increasing healthcare expenses and supportive insurance policies also fuel the U.S. market for insomnia.

Insomnia Market Trends:

Rising Prevalence of Stress, Anxiety, and Mental Health Disorders

The growing incidence of stress, anxiety, and mental health disorders is positively influencing the market. The findings from the American Psychiatric Association's yearly mental health survey for 2024 indicated that US adults experienced heightened anxiety. In 2024, 43% of adults reported feeling more anxious compared to 2023, an increase from 37% in 2023 and 32% in 2022. Modern lifestyles marked by work pressure, digital distractions, and social challenges have led to widespread sleep disturbances. Chronic stress affects hormonal balance and disrupts sleep-wake cycles, resulting in insomnia among both adults and adolescents. Moreover, anxiety and depression often coexist with sleep disorders, increasing the demand for medical interventions. The growing societal awareness around mental well-being has encouraged more individuals to seek professional help, boosting prescriptions for sleep medications and therapies. Pharmaceutical companies are developing safer, non-addictive drugs and cognitive behavioral treatments tailored for stress-related insomnia. As mental health challenges continue to escalate globally, the growing interconnection between psychological wellness and sleep health remains a central factor driving the market expansion.

Growing Aging Population and Higher Risk of Sleep Disorders

The expanding global aging population is significantly contributing to the growth of the insomnia market. As per the WHO, by the year 2030, one in every six individuals will be 60 years old or more across the globe. Older adults are more prone to sleep disturbances due to age-related physiological changes, chronic illnesses, and medication side effects. Conditions, such as arthritis, cardiovascular diseases, and neurological disorders, often interfere with normal sleep patterns. Additionally, melatonin production decreases with age, making it harder for elderly individuals to maintain regular sleep cycles. With longer life expectancy and rising healthcare awareness, more seniors are seeking medical assistance for sleep-related problems. This demographic shift is creating the growing demand for prescription medications, behavioral therapies, and natural sleep aids. Healthcare providers are focusing on holistic sleep management approaches tailored to elderly needs, making age-related sleep disorders one of the key factors driving the market forward.

Increasing Adoption of Digital Lifestyles and Screen Exposure

The growing dependence on digital devices and prolonged screen exposure is offering a favorable market outlook. As per industry reports, by Q3 2024, users globally aged 16 to 64 typically spent 6 hours and 38 minutes each day engaged with screens on different devices. The blue light released by smartphones, tablets, and computers inhibits melatonin secretion, disrupting natural sleep cycles and making it harder to fall asleep. Remote working trends, late-night entertainment, and social media usage have intensified this problem across all age groups. The constant connectivity and overstimulation also contribute to cognitive alertness, preventing adequate rest. As awareness about digital-induced sleep disruption is growing, consumers are turning to sleep aids, mobile applications, and therapies to improve rest quality. Pharmaceutical and wellness companies are addressing this modern lifestyle issue through melatonin-based supplements, behavioral therapies, and mindfulness programs. The continuous expansion of screen-driven lifestyles ensures steady demand for insomnia treatments across both clinical and consumer wellness markets.

Insomnia Industry Segmentation:

Analysis by Therapy Type:

Non-Pharmacological Therapy
- Hypnotherapy
- Cognitive Behavioral Therapy
- Medical Devices
- Others
Pharmacological Therapy
- Prescription Sleep Aids
- Over-The-Counter Sleep Aids

The pharmacological therapy segment is driven by the increasing demand for effective treatments targeting insomnia's physiological mechanisms and symptomatology. Pharmaceutical innovations aimed at developing medications with improved efficacy and safety profiles play a crucial role in expanding this segment. Research into novel drug formulations and delivery methods, including sustained-release formulations and combination therapies, enhances treatment options. Moreover, the rising prevalence of insomnia globally, exacerbated by lifestyle changes and stressors, amplifies the need for pharmacological interventions that can efficiently address sleep disturbances. Strategic collaborations between pharmaceutical companies and research institutions accelerate drug development processes, driving market competitiveness. Regulatory approvals for new drugs and treatment modalities also stimulate segment growth by expanding market access and enhancing patient trust in therapeutic efficacy.

Analysis by Drug Class:

Antidepressants
Melatonin Antagonist
Benzodiazepines
Nonbenzodiazepines
Orexin Antagonist
Others

Benzodiazepines leads the market with around 28.9% of market share in 2025. The benzodiazepines segment is driven by the increasing demand for effective anxiolytics and sedatives across various medical and psychiatric conditions. Benzodiazepines are favored for their rapid onset of action and efficacy in managing anxiety disorders, insomnia, seizures, and muscle spasms, thereby sustaining their prominence in clinical practice. Moreover, the rising prevalence of anxiety disorders globally, compounded by lifestyle stressors and mental health awareness, fuels insomnia market growth. Additionally, the segment benefits from ongoing research and development efforts aimed at improving drug formulations to minimize side effects and enhance patient compliance. Regulatory approvals for new indications and formulations also bolster market expansion, ensuring broader accessibility and application in diverse healthcare settings. Furthermore, the aging population, particularly in developed regions, contributes significantly as older adults seek treatments for anxiety-related disorders and sleep disturbances.

Analysis by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

The hospital pharmacies segment is driven by the increasing demand for specialized pharmaceutical services within healthcare facilities. These pharmacies play a crucial role in ensuring seamless medication management and distribution within hospitals, catering to inpatient and outpatient needs efficiently. Key drivers include the rising prevalence of chronic diseases requiring complex treatment regimens, which necessitate close coordination between healthcare providers and pharmacists. Additionally, advancements in hospital pharmacy automation and inventory management systems enhance operational efficiency and patient safety.

The retail pharmacies segment is driven by the increasing accessibility and convenience of healthcare services at local community settings. These pharmacies serve as accessible points of care (POC) for routine medication needs, preventive health screenings, and over-the-counter (OTC) products, catering directly to consumer demand. Key drivers include demographic trends such as aging populations requiring ongoing medication management and a shift towards self-care and wellness. Retail pharmacies also benefit from expanding healthcare insurance coverage and regulatory reforms promoting pharmacist-provided clinical services, enhancing their role in primary healthcare delivery.

The drug stores segment is driven by the increasing consumer preference for one-stop shopping experiences that combine pharmaceutical products with convenience goods. These stores offer a wide range of healthcare products, including prescription medications, over-the-counter treatments, and personal care items, appealing to consumers seeking convenience and affordability. Key drivers include strategic partnerships with healthcare providers and pharmaceutical manufacturers, which enhance product offerings and service delivery. Drug stores also benefit from location-based advantages in high-traffic areas and promotional strategies that promote health and wellness solutions.

The online pharmacies segment is driven by the increasing adoption of digital health solutions and e-commerce platforms, facilitating convenient access to medications and healthcare products. These pharmacies offer a diverse range of prescription drugs, over-the-counter medications, and health supplements, often at competitive prices and with home delivery options. Key drivers include the growing consumer demand for telemedicine services, which integrate online consultations with prescription fulfillment, enhancing accessibility and patient convenience. Online pharmacies also benefit from regulatory frameworks supporting virtual healthcare delivery and secure online transactions, ensuring patient safety and data privacy.

Regional Analysis:

North America
- United States
- Canada
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

In 2025, North America accounted for the largest market share of over 36.4%. The North America regional market is driven by the increasing awareness and diagnosis of insomnia disorders, supported by robust healthcare infrastructure and diagnostic capabilities. The region's high prevalence of lifestyle-related factors such as stress, irregular work hours, and sedentary lifestyles contribute significantly to the rising incidence of sleep disorders. Moreover, the growing elderly population in North America, characterized by a higher susceptibility to insomnia, further propels insomnia market demand. Advances in medical research and technology within the region continuously enhance diagnostic accuracy and treatment efficacy, fostering innovation in therapeutic approaches. Additionally, the proactive regulatory environment and favourable reimbursement policies stimulate market growth by facilitating quicker approvals and broader patient access to treatment options. Collaborative efforts between healthcare providers, pharmaceutical companies, and research institutions drive the development of novel therapies and personalized medicine approaches tailored to address specific patient needs.

Key Regional Takeaways:

United States Insomnia Market Analysis

The United States holds 80.00% of the market share in North America. The United States insomnia market is driven by high stress exposure, demanding work schedules, and lifestyle habits that disrupt sleep cycles across various age groups. Rising mental health burdens, particularly anxiety disorders, occupational burnout, and mood instability, have significantly increased the number of individuals seeking treatment for chronic and acute insomnia. Widespread use of electronic devices, long hours on digital screens, and dependence on mobile-based entertainment late at night are major behavioral drivers, fueling sleep disruption. The country's rapidly aging population is contributing strongly to the market expansion, as seniors frequently experience sleep fragmentation due to chronic illnesses, medication side effects, or neurocognitive decline. The US healthcare system's emphasis on specialized sleep medicine is encouraging growth in sleep labs, polysomnography services, behavioral therapy programs, and telehealth platforms offering digital cognitive behavioral therapy for insomnia (CBT-I). In addition, increasing awareness campaigns around sleep hygiene, productivity loss due to sleep deprivation, and benefits of early intervention are boosting treatment uptake. The pharmaceutical sector plays a central role, supported by extensive research and development activities (R&D) for safer hypnotics, prolonged-release melatonin, orexin receptor antagonists, and non-addictive formulations tailored for long-term use. The health and wellness sector is also stimulating demand through wearable sleep trackers, app-based monitoring solutions, and nutraceutical products, appealing to consumers seeking natural alternatives. As per the IMARC Group, the United States health and wellness market is set to attain USD 1,560 Billion by 2033, exhibiting a CAGR of 5.8% from 2025-2033.

Europe Insomnia Market Analysis

The Europe insomnia market is driven by rising mental health issues, increasing workplace stress, and lifestyle routines that heighten sleep disturbances across both urban and rural populations. The growing awareness about the long-term cognitive and physical effects of poor sleep is encouraging more individuals to seek professional help, expanding demand for behavioral therapies, prescription medicines, and OTC sleep aids. An aging demographic plays a major role, as insomnia prevalence rises with age due to chronic illnesses, pain conditions, and neurological disorders. As per the report published by Age UK, in 2024, there were 22 Million people aged over 50 in England, equivalent to two in five of the total population. Europe's strong regulatory focus on safe and clinically supported treatments is motivating the adoption of non-addictive sleep medications and structured psychological programs like CBT-I. Digital health adoption, including sleep-tracking wearables, mobile apps, and remote therapeutic programs, is gaining traction, as younger consumers are looking for technology-enabled solutions. Additionally, lifestyle factors, such as increased screen exposure, longer working hours, and urban noise pollution, contribute to sleep disruption, further supporting treatment demand.

Asia-Pacific Insomnia Market Analysis

The Asia-Pacific insomnia market is driven by rising stress levels, rapid urbanization, and increasingly demanding work schedules that disrupt sleep patterns across diverse age groups. The growing academic pressure among younger populations and high professional workloads among adults are contributing significantly to insomnia prevalence. Awareness about mental health and sleep quality is improving, encouraging more individuals to explore medical consultations, digital therapeutic tools, and OTC supplements. In October 2025, Go Spiritual, a prominent spiritual organization, initiated a groundbreaking mental health awareness campaign in India on World Mental Health Day. Rooted in the theme 'Harmony in Mind and Soul, this initiative tackled the growing crisis of mental health challenges, suicides, and social pressures by integrating spiritual insights with contemporary mental health approaches. The region's expanding middle class and increasing healthcare access support broader adoption of sleep aids, including herbal remedies, melatonin products, and prescription treatments. Technology use, especially late-night screen exposure, is also a major behavioral factor elevating sleep disturbances. Additionally, aging populations in countries like Japan, South Korea, and China are further boosting the demand.

Latin America Insomnia Market Analysis

The Latin America insomnia market is driven by rising stress, socioeconomic pressures, and increasing mental health concerns that disrupt sleep across different communities. The growing urbanization, long commutes, and extended work hours are contributing to poor sleep hygiene and higher demand for treatment options. Awareness about sleep disorders is gradually improving, encouraging interest in both pharmaceutical therapies and natural supplements. Expanding access to healthcare services and digital wellness tools also supports diagnosis and management. Additionally, lifestyle changes, increased screen usage, and an aging population are propelling the market growth in the region.

Middle East and Africa Insomnia Market Analysis

The Middle East and Africa insomnia market is driven by lifestyle stress, changing work cultures, and environmental factors, such as heat and irregular sleep routines that affect overall rest quality. Rising mental health awareness and better recognition of sleep disorders are encouraging more individuals to seek treatment. Urbanization, late-night technology use, and shift-based employment contribute to widespread sleep disruption. Improving healthcare infrastructure and the growing availability of sleep clinics, medications, and wellness supplements are supporting the market expansion. Additionally, aging population and chronic disease prevalence are driving the demand for insomnia-related solutions.

Competitive Landscape:

Key players in the insomnia market are actively engaged in a variety of strategic initiatives aimed at enhancing their market position and meeting evolving consumer demands. These initiatives include ongoing R&D efforts focused on discovering and developing new pharmacological treatments and therapies tailored to address different types and severities of insomnia. Additionally, players are investing in advanced diagnostic technologies to improve the accuracy of insomnia diagnosis, thereby enabling more personalized treatment approaches. Collaborations with healthcare providers and academic institutions are also common, facilitating the exchange of knowledge and the development of innovative treatment protocols. Furthermore, there is a growing emphasis on the integration of digital health solutions and telemedicine platforms to expand access to insomnia care and improve patient outcomes through remote monitoring and support services. Players are also navigating regulatory landscapes to secure approvals for new products and indications, ensuring compliance with evolving healthcare regulations. Market leaders are increasingly focused on sustainability and social responsibility initiatives, aligning their business strategies with broader environmental and community health goals.

The report provides a comprehensive analysis of the competitive landscape in the insomnia market with detailed profiles of all major companies, including:

Aurobindo Pharma USA
Eisai Inc.
Idorsia Pharmaceuticals, Ltd
Mallinckrodt Pharmaceuticals
Merck & Co., Inc
Neurim Pharmaceuticals LTD
Pfizer Inc
Sanofi S.A.

Key Questions Answered in This Report

1.How big is the insomnia market?
2.What is the future outlook of insomnia market?
3.What are the key factors driving the insomnia market?
4.Which region accounts for the largest insomnia market share?
5.Which are the leading companies in the global insomnia market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Insomnia Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapy Type

6.1 Non-Pharmacological Therapy
- 6.1.1 Market Trends
- 6.1.2 Key Segments
  - 6.1.2.1 Hypnotherapy
  - 6.1.2.2 Cognitive Behavioral Therapy
  - 6.1.2.3 Medical Devices
  - 6.1.2.4 Others
- 6.1.3 Market Forecast
6.2 Pharmacological Therapy
- 6.2.1 Market Trends
- 6.2.2 Key Segments
  - 6.2.2.1 Prescription Sleep Aids
  - 6.2.2.2 Over-The-Counter Sleep Aids
- 6.2.3 Market Forecast

7 Market Breakup by Drug Class

7.1 Antidepressants
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Melatonin Antagonist
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Benzodiazepines
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Nonbenzodiazepines
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Orexin Antagonist
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Drug Stores
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Online Pharmacies
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Aurobindo Pharma USA
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
- 14.3.2 Eisai Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Idorsia Pharmaceuticals, Ltd
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Mallinckrodt Pharmaceuticals
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
- 14.3.5 Merck & Co., Inc
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
  - 14.3.5.4 SWOT Analysis
- 14.3.6 Neurim Pharmaceuticals LTD
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
- 14.3.7 Pfizer Inc
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Sanofi S.A.
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Insomnia Market: Major Drivers and Challenges
Figure 2: Global: Insomnia Market: Sales Value (in Billion USD), 2020-2025
Figure 3: Global: Insomnia Market Forecast: Sales Value (in Billion USD), 2026-2034
Figure 4: Global: Insomnia Market: Breakup by Therapy Type (in %), 2025
Figure 5: Global: Insomnia Market: Breakup by Drug Class (in %), 2025
Figure 6: Global: Insomnia Market: Breakup by Distribution Channel (in %), 2025
Figure 7: Global: Insomnia Market: Breakup by Region (in %), 2025
Figure 8: Global: Insomnia (Non-Pharmacological Therapy) Market: Sales Value (in Million USD), 2020 & 2025
Figure 9: Global: Insomnia (Non-Pharmacological Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 10: Global: Insomnia (Pharmacological Therapy) Market: Sales Value (in Million USD), 2020 & 2025
Figure 11: Global: Insomnia (Pharmacological Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 12: Global: Insomnia (Antidepressants) Market: Sales Value (in Million USD), 2020 & 2025
Figure 13: Global: Insomnia (Antidepressants) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 14: Global: Insomnia (Melatonin Antagonist) Market: Sales Value (in Million USD), 2020 & 2025
Figure 15: Global: Insomnia (Melatonin Antagonist) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 16: Global: Insomnia (Benzodiazepines) Market: Sales Value (in Million USD), 2020 & 2025
Figure 17: Global: Insomnia (Benzodiazepines) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 18: Global: Insomnia (Nonbenzodiazepines) Market: Sales Value (in Million USD), 2020 & 2025
Figure 19: Global: Insomnia (Nonbenzodiazepines) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 20: Global: Insomnia (Orexin Antagonist) Market: Sales Value (in Million USD), 2020 & 2025
Figure 21: Global: Insomnia (Orexin Antagonist) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 22: Global: Insomnia (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
Figure 23: Global: Insomnia (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 24: Global: Insomnia (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
Figure 25: Global: Insomnia (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 26: Global: Insomnia (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
Figure 27: Global: Insomnia (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 28: Global: Insomnia (Drug Stores) Market: Sales Value (in Million USD), 2020 & 2025
Figure 29: Global: Insomnia (Drug Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 30: Global: Insomnia (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
Figure 31: Global: Insomnia (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 32: North America: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 33: North America: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 34: United States: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 35: United States: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 36: Canada: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 37: Canada: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 38: Asia-Pacific: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 39: Asia-Pacific: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 40: China: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 41: China: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 42: Japan: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 43: Japan: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 44: India: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 45: India: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 46: South Korea: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 47: South Korea: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 48: Australia: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 49: Australia: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 50: Indonesia: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 51: Indonesia: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 52: Others: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 53: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 54: Europe: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 55: Europe: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 56: Germany: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 57: Germany: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 58: France: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 59: France: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 60: United Kingdom: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 61: United Kingdom: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 62: Italy: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 63: Italy: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 64: Spain: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 65: Spain: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 66: Russia: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 67: Russia: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 68: Others: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 69: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 70: Latin America: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 71: Latin America: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 72: Brazil: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 73: Brazil: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 74: Mexico: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 75: Mexico: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 76: Others: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 77: Others: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 78: Middle East and Africa: Insomnia Market: Sales Value (in Million USD), 2020 & 2025
Figure 79: Middle East and Africa: Insomnia Market: Breakup by Country (in %), 2025
Figure 80: Middle East and Africa: Insomnia Market Forecast: Sales Value (in Million USD), 2026-2034
Figure 81: Global: Insomnia Industry: SWOT Analysis
Figure 82: Global: Insomnia Industry: Value Chain Analysis
Figure 83: Global: Insomnia Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Insomnia Market: Key Industry Highlights, 2025 and 2034
Table 2: Global: Insomnia Market Forecast: Breakup by Therapy Type (in Million USD), 2026-2034
Table 3: Global: Insomnia Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
Table 4: Global: Insomnia Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
Table 5: Global: Insomnia Market Forecast: Breakup by Region (in Million USD), 2026-2034
Table 6: Global: Insomnia Market: Competitive Structure
Table 7: Global: Insomnia Market: Key Players

02-2729-4219

+886-2-2729-4219